US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Onconetix Inc.

1.91

-0.0250-1.29%

Post-market: 1.910.00000.00%16:10 EST

Volume:67.52K

Turnover:136.17K

Market Cap:2.98M

PE:-0.02

High:2.13

Open:1.98

Low:1.88

Close:1.94

52wk High:179.35

52wk Low:1.88

Shares:1.56M

Float Shares:1.24M

Volume Ratio:1.07

T/O Rate:5.43%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-89.0842

EPS(LYR):-1,823.3933

ROE:-221.37%

ROA:-7.41%

PB:0.88

PE(LYR):0.00

Loading ...

Overview Company News Filings

Onconetix Inc. Files Initial Statement of Beneficial Ownership for Director Sarah Romano

Onconetix Inc. Held Annual Shareholder Meeting

Proteomedix AG Launches PRIME Study Under Onconetix Inc

Onconetix Inc - Files Prospectus For Resale Of 22.1 Million Shares Of Common Stock By Selling Stockholders - SEC Filing

BRIEF-Onconetix Inc - Files Prospectus For Resale Of 22.1 Million Shares Of Common Stock By Selling Stockholders - SEC Filing

Onconetix Inc. Announces Date for Upcoming Annual Stockholders Meeting

Onconetix Inc - Prospectus Relates to the Offer and Sale of Upto 5,100,000 Shares of Common Stock by Selling Stockholder - Filing

THOMSON REUTERS

Onconetix Inc. Announces $6.25 Million Private Placement of Series E Preferred Stock and Warrants

Veru Inc. Settles $8.8 Million Debt with Onconetix Through Cash, Preferred Stock, and Warrants Under Amended Loan Agreement

Onconetix announces financing through private placement, debt settlement

BRIEF-Onconetix Announces Financing Through $12.9 Million Private Placement Of Series D Stock And Warrants, Settlement Of $8.8 Million Debt With Veru

Onconetix Inc. Raises $12.9 Million in Private Placement of Series D Preferred Stock and Warrants

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement With Ocuvex, Inc. and Settlement of $8.8 Million Debt With Veru, Inc.

THOMSON REUTERS

BRIEF-Onconetix And Ocuvex Announce Mutual Termination Of Merger Agreement

Onconetix, Ocuvex announce mutual termination of merger agreement

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

THOMSON REUTERS

Onconetix Inc: Co, Ocuvex Determined That Pursuing Independent Paths Is in Best Interests of Stakeholders

THOMSON REUTERS

Onconetix Inc - Ocuvex Receives Nj Pharmaceutical License, Omlonti Launch Imminent

THOMSON REUTERS

Proteomedix, a Subsidiary of Onconetix, Licenses Manufacturing IP to Immunovia for Pancreatic Cancer Test

Onconetix Announces Its Subsidiary, Proteomedix, Licenses Manufacturing Ip to Immunovia Enabling Them to Independently Produce Key Reagents for Their Pancreatic Cancer Test Pancreasuretm

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ONCO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONCO\",,,,,undefined,":{"symbol":"ONCO","market":"US","secType":"STK","nameCN":"Onconetix Inc.","latestPrice":1.91,"timestamp":1766005200000,"preClose":1.935,"halted":0,"volume":67516,"hourTrading":{"tag":"盘后","latestPrice":1.91,"preClose":1.91,"latestTime":"16:10 EST","volume":103,"amount":196.73,"timestamp":1766005804813},"delay":0,"floatShares":1243200,"shares":1560668,"eps":-89.08425,"marketStatus":"Post-Mkt","change":-0.025,"latestTime":"12-17 17:53:19 EST","open":1.98,"high":2.13,"low":1.88,"amount":136171.088,"amplitude":0.129199,"askPrice":2.01,"askSize":100,"bidPrice":1.88,"bidSize":85,"shortable":3,"etf":0,"ttmEps":-89.08425,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766019600000},"marketStatusCode":4,"adr":0,"listingDate":1645160400000,"exchange":"NASDAQ","adjPreClose":1.935,"preHourTrading":{"tag":"盘前","latestPrice":1.95,"preClose":1.935,"latestTime":"09:29 EST","volume":129,"amount":251.53000500000002,"timestamp":1765981772023},"postHourTrading":{"tag":"盘后","latestPrice":1.91,"preClose":1.91,"latestTime":"16:10 EST","volume":103,"amount":196.73,"timestamp":1766005804813},"volumeRatio":1.073175},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONCO\",,,,,undefined,":{"symbol":"ONCO","floatShares":1243200,"roa":"-7.41%","roe":"-221.37%","lyrEps":-1823.3933,"volumeRatio":1.073175,"shares":1560668,"dividePrice":0,"high":2.13,"amplitude":0.129199,"preClose":1.935,"low":1.88,"week52Low":1.88,"pbRate":"0.88","psRate":"2.44","week52High":179.35,"institutionHeld":0,"latestPrice":1.91,"committee":-0.081081,"eps":-89.08425,"divideRate":0,"volume":67516,"delay":0,"ttmEps":-89.08425,"open":1.98,"prevYearClose":53.55,"prevWeekClose":2.3,"prevMonthClose":2.78,"prevQuarterClose":3.11,"fiveDayClose":2.8,"twentyDayClose":2.53,"sixtyDayClose":2.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONCO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"ONCO","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-6.25},{"market":"US","date":"2025-08-14","symbol":"ONCO","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-4.05},{"market":"US","date":"2025-06-13","symbol":"ONCO","defaultRemindTime":1749821400000,"type":"split","dateTimestamp":1749787200000,"forFactor":85,"toFactor":1,"ratio":85},{"market":"US","date":"2025-06-12","symbol":"ONCO","fiscalQuarterEnding":"2025/03","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1749700800000,"reportTimeType":"post","actualEps":0.25},{"market":"US","date":"2024-09-24","symbol":"ONCO","defaultRemindTime":1727184600000,"type":"split","dateTimestamp":1727150400000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONCO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONCO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONCO","date":"2025-12-16","current":-0.02144,"percent":0.730526,"low":-0.968106,"twenty":-0.17454,"median":-0.087938,"eighty":-0.043242,"high":-0.008728,"avg":-0.131852,"sd":0.164077,"marketCap":3074515},"quantilePoints":[{"date":"2023-12-29","current":-0.201955,"twenty":-0.205826,"median":-0.201955,"eighty":-0.193917,"marketCap":3691085},{"date":"2024-01-05","current":-0.194459,"twenty":-0.201955,"median":-0.195264,"eighty":-0.193719,"marketCap":3554077},{"date":"2024-01-12","current":-0.190736,"twenty":-0.197125,"median":-0.193719,"eighty":-0.190736,"marketCap":3486030},{"date":"2024-01-19","current":-0.173836,"twenty":-0.19628,"median":-0.192899,"eighty":-0.180094,"marketCap":3177158},{"date":"2024-01-26","current":-0.342039,"twenty":-0.19628,"median":-0.189647,"eighty":-0.1728,"marketCap":6251352},{"date":"2024-02-02","current":-0.174037,"twenty":-0.202407,"median":-0.192246,"eighty":-0.173635,"marketCap":3180835},{"date":"2024-02-09","current":-0.164782,"twenty":-0.198091,"median":-0.186679,"eighty":-0.170436,"marketCap":3011681},{"date":"2024-02-16","current":-0.205696,"twenty":-0.198091,"median":-0.184801,"eighty":-0.168042,"marketCap":3759458},{"date":"2024-02-23","current":-0.206429,"twenty":-0.205989,"median":-0.188558,"eighty":-0.169852,"marketCap":3772853},{"date":"2024-03-01","current":-0.208872,"twenty":-0.20842,"median":-0.192572,"eighty":-0.172015,"marketCap":3817502},{"date":"2024-03-08","current":-0.22182,"twenty":-0.213025,"median":-0.193719,"eighty":-0.17277,"marketCap":4054143},{"date":"2024-03-15","current":-0.201665,"twenty":-0.217422,"median":-0.196597,"eighty":-0.172951,"marketCap":3685787},{"date":"2024-03-22","current":-0.203986,"twenty":-0.21515,"median":-0.197125,"eighty":-0.173514,"marketCap":3728204},{"date":"2024-03-28","current":-0.2002,"twenty":-0.212952,"median":-0.198734,"eighty":-0.173916,"marketCap":3658998},{"date":"2024-04-05","current":-0.204475,"twenty":-0.211193,"median":-0.198734,"eighty":-0.174238,"marketCap":3737134},{"date":"2024-04-12","current":-0.093154,"twenty":-0.209947,"median":-0.197125,"eighty":-0.174238,"marketCap":3484866},{"date":"2024-04-19","current":-0.079022,"twenty":-0.209385,"median":-0.195935,"eighty":-0.172739,"marketCap":2956187},{"date":"2024-04-26","current":-0.07186,"twenty":-0.2087,"median":-0.194214,"eighty":-0.166713,"marketCap":2688255},{"date":"2024-05-03","current":-0.067443,"twenty":-0.208428,"median":-0.193586,"eighty":-0.15949,"marketCap":2523030},{"date":"2024-05-10","current":-0.066787,"twenty":-0.208202,"median":-0.192246,"eighty":-0.083892,"marketCap":2498469},{"date":"2024-05-17","current":-0.084155,"twenty":-0.207504,"median":-0.190061,"eighty":-0.075083,"marketCap":3148205},{"date":"2024-05-24","current":-0.069112,"twenty":-0.206722,"median":-0.188558,"eighty":-0.074211,"marketCap":3157136},{"date":"2024-05-31","current":-0.116278,"twenty":-0.206282,"median":-0.18621,"eighty":-0.07464,"marketCap":5311760},{"date":"2024-06-07","current":-0.08705,"twenty":-0.205452,"median":-0.178162,"eighty":-0.074985,"marketCap":3976563},{"date":"2024-06-14","current":-0.070578,"twenty":-0.204475,"median":-0.174289,"eighty":-0.074605,"marketCap":3224120},{"date":"2024-06-21","current":-0.075759,"twenty":-0.204269,"median":-0.173433,"eighty":-0.074474,"marketCap":3460793},{"date":"2024-06-28","current":-0.100148,"twenty":-0.204171,"median":-0.17293,"eighty":-0.07408,"marketCap":4574945},{"date":"2024-07-05","current":-0.078056,"twenty":-0.203986,"median":-0.171849,"eighty":-0.074605,"marketCap":3565733},{"date":"2024-07-12","current":-0.070578,"twenty":-0.203986,"median":-0.1678,"eighty":-0.07371,"marketCap":3224120},{"date":"2024-07-15","current":-0.074977,"twenty":-0.203742,"median":-0.166895,"eighty":-0.073758,"marketCap":3425069},{"date":"2024-08-02","current":-0.097024,"twenty":-0.203498,"median":-0.165989,"eighty":-0.073806,"marketCap":4432207},{"date":"2024-08-09","current":-0.087113,"twenty":-0.202765,"median":-0.164732,"eighty":-0.074211,"marketCap":3979455},{"date":"2024-08-16","current":-0.091286,"twenty":-0.202441,"median":-0.148887,"eighty":-0.074675,"marketCap":4170088},{"date":"2024-08-23","current":-0.103936,"twenty":-0.201937,"median":-0.114182,"eighty":-0.074801,"marketCap":4747943},{"date":"2024-08-30","current":-0.075134,"twenty":-0.201812,"median":-0.103936,"eighty":-0.074889,"marketCap":3991369},{"date":"2024-09-06","current":-0.071275,"twenty":-0.201372,"median":-0.101719,"eighty":-0.07464,"marketCap":3786324},{"date":"2024-09-13","current":-0.074303,"twenty":-0.199931,"median":-0.100613,"eighty":-0.073472,"marketCap":3947190},{"date":"2024-09-20","current":-0.06477,"twenty":-0.198832,"median":-0.097806,"eighty":-0.072904,"marketCap":3440758},{"date":"2024-09-27","current":-0.047041,"twenty":-0.198734,"median":-0.097089,"eighty":-0.072123,"marketCap":2498940},{"date":"2024-10-04","current":-0.702586,"twenty":-0.201861,"median":-0.097806,"eighty":-0.072322,"marketCap":37323522},{"date":"2024-10-11","current":-0.804153,"twenty":-0.203742,"median":-0.100613,"eighty":-0.072761,"marketCap":42719049},{"date":"2024-10-18","current":-0.880664,"twenty":-0.205452,"median":-0.101719,"eighty":-0.072874,"marketCap":46783580},{"date":"2024-10-25","current":-0.626146,"twenty":-0.208304,"median":-0.106675,"eighty":-0.072904,"marketCap":33262793},{"date":"2024-10-31","current":-0.46218,"twenty":-0.209727,"median":-0.114182,"eighty":-0.073022,"marketCap":24552412},{"date":"2024-11-08","current":-0.379425,"twenty":-0.217422,"median":-0.148887,"eighty":-0.073022,"marketCap":20156203},{"date":"2024-11-15","current":-0.254511,"twenty":-0.219865,"median":-0.164732,"eighty":-0.073315,"marketCap":13520416},{"date":"2024-11-22","current":-0.17644,"twenty":-0.219499,"median":-0.165989,"eighty":-0.073412,"marketCap":9373049},{"date":"2024-11-29","current":-0.107738,"twenty":-0.218815,"median":-0.165889,"eighty":-0.07365,"marketCap":5723366},{"date":"2024-12-06","current":-0.098369,"twenty":-0.217666,"median":-0.160355,"eighty":-0.073901,"marketCap":5225682},{"date":"2024-12-13","current":-0.075065,"twenty":-0.217422,"median":-0.144138,"eighty":-0.074232,"marketCap":3873640},{"date":"2024-12-20","current":-0.057866,"twenty":-0.214393,"median":-0.114182,"eighty":-0.073393,"marketCap":2986104},{"date":"2024-12-27","current":-0.056259,"twenty":-0.21261,"median":-0.110145,"eighty":-0.072963,"marketCap":2903156},{"date":"2025-01-03","current":-0.104658,"twenty":-0.211193,"median":-0.107738,"eighty":-0.072874,"marketCap":5400701},{"date":"2025-01-10","current":-0.087844,"twenty":-0.210021,"median":-0.107738,"eighty":-0.072904,"marketCap":4533072},{"date":"2025-01-17","current":-0.082411,"twenty":-0.209556,"median":-0.104481,"eighty":-0.073022,"marketCap":4252710},{"date":"2025-01-24","current":-0.077155,"twenty":-0.208872,"median":-0.103034,"eighty":-0.073022,"marketCap":3981472},{"date":"2025-01-31","current":-0.090802,"twenty":-0.208442,"median":-0.10198,"eighty":-0.073315,"marketCap":4685695},{"date":"2025-02-07","current":-0.105075,"twenty":-0.208406,"median":-0.10224,"eighty":-0.073412,"marketCap":5422267},{"date":"2025-02-14","current":-0.087185,"twenty":-0.207895,"median":-0.101296,"eighty":-0.07371,"marketCap":4499063},{"date":"2025-02-21","current":-0.067511,"twenty":-0.207113,"median":-0.100929,"eighty":-0.073393,"marketCap":3483788},{"date":"2025-02-28","current":-0.049315,"twenty":-0.206527,"median":-0.100148,"eighty":-0.072875,"marketCap":2544824},{"date":"2025-03-07","current":-0.036777,"twenty":-0.205843,"median":-0.098528,"eighty":-0.072195,"marketCap":1897835},{"date":"2025-03-14","current":-0.020864,"twenty":-0.204719,"median":-0.098369,"eighty":-0.071225,"marketCap":1076656},{"date":"2025-03-21","current":-0.020944,"twenty":-0.204269,"median":-0.097978,"eighty":-0.070572,"marketCap":1080803},{"date":"2025-03-28","current":-0.017312,"twenty":-0.204032,"median":-0.097741,"eighty":-0.069818,"marketCap":893342},{"date":"2025-04-04","current":-0.0122,"twenty":-0.203986,"median":-0.097063,"eighty":-0.069089,"marketCap":629570},{"date":"2025-04-11","current":-0.009323,"twenty":-0.203009,"median":-0.096444,"eighty":-0.068134,"marketCap":481094},{"date":"2025-04-17","current":-0.00958,"twenty":-0.202765,"median":-0.095559,"eighty":-0.067511,"marketCap":494366},{"date":"2025-04-25","current":-0.011091,"twenty":-0.202279,"median":-0.093131,"eighty":-0.066512,"marketCap":572336},{"date":"2025-05-02","current":-0.012554,"twenty":-0.201928,"median":-0.092586,"eighty":-0.065058,"marketCap":647818},{"date":"2025-05-09","current":-0.011702,"twenty":-0.201763,"median":-0.090913,"eighty":-0.063884,"marketCap":603856},{"date":"2025-05-16","current":-0.011991,"twenty":-0.200786,"median":-0.088907,"eighty":-0.05784,"marketCap":618787},{"date":"2025-05-23","current":-0.023761,"twenty":-0.199394,"median":-0.088096,"eighty":-0.054651,"marketCap":1226160},{"date":"2025-05-30","current":-0.068768,"twenty":-0.198807,"median":-0.087659,"eighty":-0.054651,"marketCap":3548673},{"date":"2025-06-06","current":-0.052528,"twenty":-0.198734,"median":-0.087113,"eighty":-0.054651,"marketCap":3082910},{"date":"2025-06-13","current":-0.058572,"twenty":-0.19856,"median":-0.086807,"eighty":-0.054651,"marketCap":3286955},{"date":"2025-06-20","current":-0.037197,"twenty":-0.198065,"median":-0.086363,"eighty":-0.052105,"marketCap":2087452},{"date":"2025-06-27","current":-0.043242,"twenty":-0.196958,"median":-0.084244,"eighty":-0.047082,"marketCap":2426662},{"date":"2025-07-03","current":-0.043242,"twenty":-0.196291,"median":-0.084155,"eighty":-0.044358,"marketCap":2426662},{"date":"2025-07-11","current":-0.040638,"twenty":-0.196069,"median":-0.082194,"eighty":-0.043707,"marketCap":2280541},{"date":"2025-07-18","current":-0.033199,"twenty":-0.195802,"median":-0.081722,"eighty":-0.043242,"marketCap":1863050},{"date":"2025-07-25","current":-0.033571,"twenty":-0.194459,"median":-0.079938,"eighty":-0.040587,"marketCap":1883925},{"date":"2025-08-01","current":-0.033106,"twenty":-0.194214,"median":-0.079059,"eighty":-0.039615,"marketCap":1857832},{"date":"2025-08-08","current":-0.024829,"twenty":-0.194214,"median":-0.078385,"eighty":-0.038313,"marketCap":1393374},{"date":"2025-08-15","current":-0.08511,"twenty":-0.193719,"median":-0.078056,"eighty":-0.037197,"marketCap":4776225},{"date":"2025-08-22","current":-0.098303,"twenty":-0.193453,"median":-0.078868,"eighty":-0.037476,"marketCap":4343428},{"date":"2025-08-29","current":-0.10495,"twenty":-0.192899,"median":-0.079376,"eighty":-0.038127,"marketCap":4637112},{"date":"2025-09-05","current":-0.100402,"twenty":-0.192377,"median":-0.080109,"eighty":-0.038276,"marketCap":4436170},{"date":"2025-09-12","current":-0.109498,"twenty":-0.191038,"median":-0.081809,"eighty":-0.038536,"marketCap":4838053},{"date":"2025-09-19","current":-0.10495,"twenty":-0.190587,"median":-0.082411,"eighty":-0.03889,"marketCap":4637112},{"date":"2025-09-26","current":-0.111597,"twenty":-0.189768,"median":-0.084184,"eighty":-0.039262,"marketCap":4930795},{"date":"2025-10-03","current":-0.110197,"twenty":-0.189377,"median":-0.08511,"eighty":-0.039559,"marketCap":4868967},{"date":"2025-10-10","current":-0.144131,"twenty":-0.188712,"median":-0.086363,"eighty":-0.039737,"marketCap":6368300},{"date":"2025-10-17","current":-0.12174,"twenty":-0.188197,"median":-0.086815,"eighty":-0.039794,"marketCap":5378958},{"date":"2025-10-24","current":-0.117582,"twenty":-0.186589,"median":-0.087149,"eighty":-0.040024,"marketCap":5195267},{"date":"2025-10-31","current":-0.132966,"twenty":-0.185889,"median":-0.087844,"eighty":-0.040486,"marketCap":5875000},{"date":"2025-11-07","current":-0.093673,"twenty":-0.185003,"median":-0.088278,"eighty":-0.040628,"marketCap":4138852},{"date":"2025-11-14","current":-0.085873,"twenty":-0.182146,"median":-0.088907,"eighty":-0.041415,"marketCap":3794224},{"date":"2025-11-21","current":-0.073999,"twenty":-0.178698,"median":-0.088096,"eighty":-0.042023,"marketCap":3636356},{"date":"2025-11-28","current":-0.088291,"twenty":-0.177065,"median":-0.087968,"eighty":-0.042796,"marketCap":4338657},{"date":"2025-12-05","current":-0.09369,"twenty":-0.175481,"median":-0.088091,"eighty":-0.043242,"marketCap":4603970},{"date":"2025-12-12","current":-0.073364,"twenty":-0.174661,"median":-0.088061,"eighty":-0.043242,"marketCap":3605143},{"date":"2025-12-16","current":-0.062566,"twenty":-0.17454,"median":-0.087938,"eighty":-0.043242,"marketCap":3074515}],"updateTime":1766011996912},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONCO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2591568216","title":"Onconetix Inc. Files Initial Statement of Beneficial Ownership for Director Sarah Romano","url":"https://stock-news.laohu8.com/highlight/detail?id=2591568216","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591568216?lang=en_us&edition=fundamental","pubTime":"2025-12-13 07:05","pubTimestamp":1765580729,"startTime":"0","endTime":"0","summary":"Onconetix Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Sarah Romano as the beneficial owner in her role as Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL6FTR06:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Onconetix Inc. Files Initial Statement of Beneficial Ownership for Director Sarah Romano","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2590559515","title":"Onconetix Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590559515","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590559515?lang=en_us&edition=fundamental","pubTime":"2025-12-11 06:01","pubTimestamp":1765404087,"startTime":"0","endTime":"0","summary":"Onconetix Inc. held its annual meeting on December 5, 2025. Shareholders approved the issuance of up to 4,424,080 shares of Common Stock upon conversion of Series D Preferred Stock and up to 4,362,827 shares of Common Stock upon the exercise of certain warrants issued in connection with a private placement that closed on September 22, 2025. Approval was also granted for the issuance of up to 2,025,223 shares of Common Stock upon conversion of Series E Preferred Stock and up to 2,025,223 shares of Common Stock upon exercise of certain warrants related to a private placement that closed on October 1, 2025. The appointment of MaloneBailey, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. Shareholders also approved the potential adjournment of the annual meeting to solicit additional proxies if needed.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL4Mhsg3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2590053383","title":"Proteomedix AG Launches PRIME Study Under Onconetix Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590053383","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590053383?lang=en_us&edition=fundamental","pubTime":"2025-12-10 22:28","pubTimestamp":1765376932,"startTime":"0","endTime":"0","summary":"Proteomedix AG, Subsidiary of Onconetix Inc., Amends License Agreement with Labcorp for Proclarix Validation Study. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL7fStfx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1059921491.USD","BK4139","BK4550","LU0048573561.USD","BK4588","ONCO","LU0251142724.SGD","LU0006061336.USD","BK4196","LU0742534661.SGD","LU0251131958.USD","BK4585","LH"],"gpt_icon":0},{"id":"2584925970","title":"Onconetix Inc - Files Prospectus For Resale Of 22.1 Million Shares Of Common Stock By Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584925970","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584925970?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:33","pubTimestamp":1763569994,"startTime":"0","endTime":"0","summary":"Nov 5 (Reuters) - Onconetix Inc ::*ONCONETIX INC - FILES PROSPECTUS FOR RESALE OF 22.1 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 04-NOV-202523:01:04 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD73Rh8T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2581953227","title":"BRIEF-Onconetix Inc - Files Prospectus For Resale Of 22.1 Million Shares Of Common Stock By Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581953227","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581953227?lang=en_us&edition=fundamental","pubTime":"2025-11-05 07:01","pubTimestamp":1762297264,"startTime":"0","endTime":"0","summary":"BRIEF-Onconetix Inc - Files Prospectus For Resale Of 22.1 Million Shares Of Common Stock By Selling Stockholders - SEC FilingNov 5  - Onconetix Inc ONCO.O:ONCONETIX INC - FILES PROSPECTUS FOR RESALE OF 22.1 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILINGSource text: [ID:n0001213900-25-106177]Further company coverage: ONCO.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2579756489","title":"Onconetix Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2579756489","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579756489?lang=en_us&edition=fundamental","pubTime":"2025-10-29 18:03","pubTimestamp":1761732197,"startTime":"0","endTime":"0","summary":"Onconetix Inc. will hold its Annual Meeting on December 5, 2025. During the meeting, shareholders will be asked to vote on five proposals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL2KqsCG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2575714289","title":"Onconetix Inc - Prospectus Relates to the Offer and Sale of Upto 5,100,000 Shares of Common Stock by Selling Stockholder - Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2575714289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575714289?lang=en_us&edition=fundamental","pubTime":"2025-10-16 18:08","pubTimestamp":1760609308,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nFWN3VW2WF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2572350209","title":"Onconetix Inc. Announces $6.25 Million Private Placement of Series E Preferred Stock and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2572350209","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572350209?lang=en_us&edition=fundamental","pubTime":"2025-10-03 20:16","pubTimestamp":1759493809,"startTime":"0","endTime":"0","summary":"Onconetix Inc. has announced the completion of a private placement financing with institutional investors, raising approximately $6.25 million. The company sold a total of 7,813 shares of Series E convertible preferred stock, which are convertible into common shares, along with warrants to purchase 2,025,223 common shares. As part of the transaction, Onconetix entered into a registration rights agreement with the investors, granting them certain rights regarding the registration of the underlying common shares. The Series E preferred stock carries a stated value of $1,000 per share and ranks pari passu with the company's Series C and Series D preferred stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL34R9Kv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2570886247","title":"Veru Inc. Settles $8.8 Million Debt with Onconetix Through Cash, Preferred Stock, and Warrants Under Amended Loan Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2570886247","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570886247?lang=en_us&edition=fundamental","pubTime":"2025-09-26 21:00","pubTimestamp":1758891625,"startTime":"0","endTime":"0","summary":"**Veru Inc. Settles Outstanding Promissory Notes with Onconetix, Inc.** Veru Inc. has announced the termination of its outstanding loan agreements with Onconetix, Inc. , following a recently executed Settlement Agreement. As of September 22, 2025, a total of $8.8 million was owed to Veru under two promissory notes related to a previous asset purchase. Under the terms of the settlement, Veru agreed to accept a reduced cash payment of approximately $6.3 million, along with 3,125 shares of Onconetix's Series D Convertible Preferred Stock  and 846,975 warrants to purchase common stock, in full satisfaction of all outstanding obligations. The transaction was completed on September 24, 2025, with all related agreements and notes officially terminated upon payment. There is no assurance as to the timing or amount of any future proceeds Veru may receive from the preferred shares or warrants.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL6Qc9YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4183","BK4557","VERU","BK4584","ONCO","BK4007"],"gpt_icon":0},{"id":"2570888521","title":"Onconetix announces financing through private placement, debt settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2570888521","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570888521?lang=en_us&edition=fundamental","pubTime":"2025-09-26 20:40","pubTimestamp":1758890445,"startTime":"0","endTime":"0","summary":"Onconetix (ONCO) announced the September 22, 2025 signing and closing of a private placement of shares of the Company’s Series D Convertible Prefer...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onconetix-announces-financing-through-private-placement-debt-settlement-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onconetix-announces-financing-through-private-placement-debt-settlement-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2570166885","title":"BRIEF-Onconetix Announces Financing Through $12.9 Million Private Placement Of Series D Stock And Warrants, Settlement Of $8.8 Million Debt With Veru","url":"https://stock-news.laohu8.com/highlight/detail?id=2570166885","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570166885?lang=en_us&edition=fundamental","pubTime":"2025-09-26 20:40","pubTimestamp":1758890400,"startTime":"0","endTime":"0","summary":"BRIEF-Onconetix Announces Financing Through $12.9 Million Private Placement Of Series D Stock And Warrants, Settlement Of $8.8 Million Debt With VeruSept 26 (Reuters) - Onconetix Inc ONCO.O:ONCONETIX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nTUA6YGW3Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2570388565","title":"Onconetix Inc. Raises $12.9 Million in Private Placement of Series D Preferred Stock and Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2570388565","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570388565?lang=en_us&edition=fundamental","pubTime":"2025-09-26 20:30","pubTimestamp":1758889812,"startTime":"0","endTime":"0","summary":"Onconetix Inc. , a commercial-stage biotechnology company specializing in men's health and oncology, has announced the completion of a private placement, raising approximately $12.9 million. The financing involved the issuance of Series D Convertible Preferred Stock and warrants to purchase up to 4,362,827 shares of common stock. Of the total amount raised, about $9.3 million was paid in cash, with the remainder used to offset existing obligations to certain investors. The Series D Preferred Stock is initially convertible into an equivalent number of common shares, subject to anti-dilution adjustments. The warrants have an exercise price of $3.6896 per share and will be exercisable for three years from the date of issuance. Proceeds from the offering will be used to settle debt with Veru, Inc., cover costs related to a terminated merger with Ocuvex, Inc., and for general corporate purposes and working capital.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL7RQXS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","ONCO","LU2210149790.SGD","NDAQ","BK4588","IE00B3QW5Z07.USD","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","LU2210150020.SGD","BK4139"],"gpt_icon":0},{"id":"2570885327","title":"Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement With Ocuvex, Inc. and Settlement of $8.8 Million Debt With Veru, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2570885327","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570885327?lang=en_us&edition=fundamental","pubTime":"2025-09-26 20:30","pubTimestamp":1758889800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nTUA6YGW3Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2570858528","title":"BRIEF-Onconetix And Ocuvex Announce Mutual Termination Of Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2570858528","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570858528?lang=en_us&edition=fundamental","pubTime":"2025-09-26 20:28","pubTimestamp":1758889713,"startTime":"0","endTime":"0","summary":"BRIEF-Onconetix And Ocuvex Announce Mutual Termination Of Merger AgreementSept 26 (Reuters) - Onconetix Inc ONCO.O:JOINT PRESS RELEASE: ONCONETIX AND OCUVEX ANNOUNCE MUTUAL TERMINATION OF MERGER AGREE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nTUA5W20S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2570883704","title":"Onconetix, Ocuvex announce mutual termination of merger agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2570883704","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570883704?lang=en_us&edition=fundamental","pubTime":"2025-09-26 20:20","pubTimestamp":1758889226,"startTime":"0","endTime":"0","summary":"Onconetix (ONCO) and Ocuvex Therapeutics announced the mutual termination of their previously announced definitive merger agreement, dated July 16,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onconetix-ocuvex-announce-mutual-termination-of-merger-agreement-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onconetix-ocuvex-announce-mutual-termination-of-merger-agreement-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2570888317","title":"Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2570888317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570888317?lang=en_us&edition=fundamental","pubTime":"2025-09-26 20:15","pubTimestamp":1758888900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nTUA5W20S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2570883175","title":"Onconetix Inc:  Co, Ocuvex Determined That Pursuing Independent Paths Is in Best Interests of Stakeholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2570883175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570883175?lang=en_us&edition=fundamental","pubTime":"2025-09-26 20:15","pubTimestamp":1758888900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nTUA5W20S5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2570883173","title":"Onconetix Inc - Ocuvex Receives Nj Pharmaceutical License, Omlonti Launch Imminent","url":"https://stock-news.laohu8.com/highlight/detail?id=2570883173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570883173?lang=en_us&edition=fundamental","pubTime":"2025-09-26 20:15","pubTimestamp":1758888900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nTUA5W20S5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2569781099","title":"Proteomedix, a Subsidiary of Onconetix, Licenses Manufacturing IP to Immunovia for Pancreatic Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2569781099","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569781099?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:00","pubTimestamp":1758542426,"startTime":"0","endTime":"0","summary":"Onconetix Inc.'s wholly owned subsidiary, Proteomedix AG, has signed a licensing agreement with Immunovia AB, a pancreatic cancer diagnostics company. Under this agreement, Proteomedix will provide Immunovia with master cells to produce antibodies related to three biomarkers in the PancreaSure test, along with a license for manufacturing reagents. In exchange, Immunovia will make payments totaling $700,000 and a 3% royalty on net sales from 2026 to 2032.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via GlobeNewswire  on September 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL4qxYCc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","LU2210149790.SGD","BK4588","ONCO","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","BK4139","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2569810347","title":"Onconetix Announces Its Subsidiary, Proteomedix, Licenses Manufacturing Ip to Immunovia Enabling Them to Independently Produce Key Reagents for Their Pancreatic Cancer Test Pancreasuretm","url":"https://stock-news.laohu8.com/highlight/detail?id=2569810347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569810347?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:00","pubTimestamp":1758542403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nTUACFVDY4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}